Renal Cell Carcinoma

• FDA label_change · 2024-05-20
  FDA Approved: PAZOPANIB — Supplemental Application (Apotex Corp.)

  FDA approved a supplemental application for pazopanib by Apotex Corp. (ANDA 217713), likely involving labeling or other post-approval change…

• FDA label_change · 2012-02-16
  FDA Approved: YERVOY — Supplemental Application (E.R. Squibb & Sons, L.L.C.)

  FDA announces a supplemental application for YERVOY (ipilimumab) submitted by E.R. Squibb & Sons, L.L.C., relating to labeling changes for t…

• FDA label_change · 2011-10-21
  FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) from Novartis Pharmaceuticals Corporation, resulting in chang…

• FDA label_change · 2010-07-06
  FDA Approved: PROLEUKIN — Supplemental Application (Iovance Biotherapeutics, Inc)

  FDA approved a supplemental application for PROLEUKIN (aldesleukin) submitted by Iovance Biotherapeutics, Inc.